Rapamycin Ta Gasa Babban Gwajin Tsawon Rayuwa a Ɗan Adam – Menene Sakamakon?
Rapamycin an ɗauke ta a matsayin maganin da zai iya tsawaita rayuwa, amma gwajin da ya yi amfani da bayanan dubban marasa lafiya masu canjin koda ya nuna ba a samu wani bambanci mai ma'ana a tsawon rai ba – shekarun rayuwa na matsakaici sun kasance 64.6 ga masu sha da 64.3 ga wadanda ba su sha. Wannan shi ne abin da binciken ya bayyana da kuma abin da bai bayyana ba.
Ursolic Acid, sinadarin da ke cikin fatar tuffa, yana kare tsoka a berayen da suka yi kiba
Sinadarin ursolic acid da ke cikin fatar tuffa ya nuna ƙarfi wajen kare tsoka a berayen da suka yi kiba, haka kuma ɗan'uwansa oleanolic acid ya yi haka. A berayen da aka ciyar da abincin mai da kuma ƙwayoyin tsoka da suka fuskanci ƙarancin kitse, duka biyun sun inganta sarrafa sukari, rage raguwar tsoka, kuma suka tallafa wa mitochondria. Hanyoyin da aka ba da shawara sun haɗa da farfado da siginar IRS/AKT/mTOR, rage lalacewar da FOXO1 ke haifarwa, da alaka mai yiwuwa da PSMB1. Amma binciken an yi shi ne a dabbobi da ƙwayoyin sel, ba a kan mutane ba, don haka ba ya nufin cewa sinadaran suna kare tsoka a mutum ko magance sarcopenia.
Rapamycin Ba Zai Iya Kai Zuwa Kwakwalwa Ba? Dalilin Da Yasa Wannan Karya Ke Karyewa
Kalmar “Rapamycin ba zai iya shiga kwakwalwa ba” ta zama ruwan dare a tsakanin masu sha'awar tsawaita rai. Binciken sabo a mujallar *Journal of Alzheimer's Disease* ya nuna cewa hujjar da ke goyon bayan wannan maganar tana dogara ne kan hanyar gwaji marar inganci, kuma ƙarin shaidu na nuni da akasin haka. Wannan labarin yana tantance hujjojin da ke tallafawa, waɗanda ba su tallafawa ba, da kuma abin da masana ke bukatar su bincika a gaba.